Abstract
The effects of the putative atypical antipsychotics olanzapine and ICI 204,636 on behavioural responses to the selective “D2-like” dopamine receptor agonist RU 24213 and to the selective “D1-like” agonist A 68930 were compared with those of the prototype atypical antipsychotic clozapine, the selective D1-like antagonist SCH 23390 and the selective D2-like antagonist YM 09151-2. Olanzapine (0.4–2.0 mg/kg) and ICI 204,636 (4.0–36.0 mg/kg), like clozapine (4.0–36.0 mg/kg) and SCH 23390 (0.01–1.0 mg/kg), effected at best modest reduction in typical sniffing and locomotor responses and, with the exception of ICI 204,636, released episodes of atypical myoclonic jerking to RU 24213 (12.5 mg/kg); a high dose of olanzapine (10.0 mg/kg), like YM 09151-2 (0.005–0.5 mg/kg), blocked all responsivity to RU 24213. Conversely, olanzapine (0.4–2.0 mg/kg) and ICI 204,636 (4.0–36.0 mg/kg), like clozapine (4.0–12.0 mg/kg) and SCH 23390 (0.01–0.1 mg/kg), readily blocked typical grooming responses to A 68930 (0.5 mg/kg); YM 09151-2 failed to block grooming and exerted more variable effects. Olanzapine and, to a lesser extent, ICI 204,636 share with clozapine a preferential action to attenuate D1-mediated function; given their lack of selective affinity for D1-like receptors, this common effect may be exerted at an alternative level of synaptic function. The action of olanzapine and particularly ICI 204,636 to release additional episodes of atypical vacuous chewing to A 68930 indicates some deviation from a wholly clozapine-like profile, the clinical significance of which remains to be specified.
This is a preview of subscription content, log in via an institution to check access.
Similar content being viewed by others
References
Andersen PH, Braestrup C (1986) Evidence for different states of the dopamine D1 receptor: clozapine and fluperlapine may preferentially label an adenylate cyclase-coupled state of the D1 receptor. J Neurochem 47:1822–1831
Andersen PH, Gingrich JA, Bates MD, Dearry A, Falardeau P, Senogles SE, Caron M (1990) Dopamine receptor subtypes: beyond the D-1/D-2 classification. Trends Pharmacol Sci 11:231–236
Andersen PH, Gronvald FC, Hohlweg R, Hansen LB, Guddal E, Braestrup C, Nielsen EB (1992) NNC-112, NNC-687 and NNC-756, new selective and highly potent D1 receptor antagonists. Eur J Pharmacol 219:45–52
Arnt J, Hyttel J (1986) Inhibition of SK&F 38393- and pergolide-induced circling in rats with unilateral 6-OHDA lesion is correlated to dopamine D-1 and D-2 receptor affinities in vitro. J Neural Transm 67:225–240
Baldessarini RJ, Frankenburg FR (1991) Clozapine: a novel antipsychotic agent. N Engl J Med 324:746–754
Barlow RB (1983) Biodata handling with microcomputers. Elsevier, Amsterdam
Chipkin RE, Latranyi MB (1987) Similarity of clozapine and SCH 23390 in reserpinized rats suggest a common mechanism of action. Eur J Pharmacol 136:371–375
Chipkin RE, Iorio LC, Coffin VL, McQuade RD, Berger JG, Barnett A (1988) Pharmacological profile of SCH 39166: a dopamine D-1 selective benzonaphthazepine with potential antipsychotic activity. J Pharmacol Exp Ther 247:1093–1102
Collins P, Broekkamp CLE, Jenner P, Marsden CD (1991) Drugs acting at D-1 and D-2 receptors induce identical purposeless chewing in rats which can be differentiated by cholinergic manipulation. Psychopharmacology 103:503–512
Coward DM, Imperato A, Urwyler S, White TG (1989) Biochemical and behavioural properties of clozapine. Psychopharmacology 99 [Supplement]:S6-S12
Criswell HE, Mueller RA, Breese GR (1989) Clozapine antagonism of D1 and D2 dopamine receptor-mediated behaviours. Eur J Pharmacol 159:141–147
Daly SA, Waddington JL (1992) Two directions of dopamine D-1/D-2 receptor interaction in studies of behavioural regulation: a finding generic to four new, selective dopamine D-1 antagonists. Eur J Pharmacol 213:251–258
Daly SA, Waddington JL (1993) Behavioural evidence for “D-1-like” dopamine receptor subtypes in rat brain using the new isochroman agonist A 68930 and isoquinoline antagonist BW 737C. Psychopharmacology 113:45–50
Daly SA, Waddington JL (1994) The effects of clozapine on behavioural responses to the selective “D1-like” dopamine receptor agonist, A 68930, and to the selective “D2-like” agonist, RU 24213. Br J Pharmacol 113:839–844
DeNinno MP, Schoenleber R, MacKenzie R, Britton DR, Asin KE, Briggs C, Trugman JM, Ackerman M, Artman L, Bednarz L, Bhatt R, Curzon P, Gomez E, Kang CH, Stittsworth J, Kebabian JW (1991) A 68930: a potent agonist selective for the dopamine D-1 receptor. Eur J Pharmacol 1991:209–219
Deutch AY, Moghaddam B, Innis RB (1991) Mechanisms of action of atypical antipsychotic drugs: implications for novel therapeutic strategies for schizophrenia. Schizophr Res 4:121–156
Deveney AM, Waddington JL (1995) Pharmacological analysis of behavioural responses to SK&F 83959 in relation to D1-like dopamine receptors not linked adenylyl cyclase. Br J Pharmacol (in press)
Downes RP, Waddington JL (1993) Grooming and vacuous chewing induced by SK&F 83959, an agonist of dopamine “D1-like” receptors that inhibits dopamine-sensitive adenylyl cyclase. Eur J Pharmacol 234:135–136
Ellenbroek BA, Artz MT, Cools AR (1991) The involvement of dopamine D1 and D2 receptors in the effects of the classical neuroleptic haloperidol and the atypical neuroleptic clozapine. Eur J Pharmacol 196:103–108
Euvrard C, Ferland L, DiPaulo T, Beaulieu M, Labrie F, Oberlander C, Raynaud JP, Bossier JR (1980) Activity of two new potent dopaminergic agonists at the striatal and anterior pituitary levels. Neuropharmacology 19:379–386
Farde L, Nordstrom AL, Wiesel FA, Pauli S, Halldin C, Sedvall G (1992) Positron emission tomographic analysis of central D1 and D2 dopamine receptor occupancy in patients treated with classical neuroleptics and clozapine. Arch Gen Psychiatry 49:538–544
Heal DJ, Czudek C, Buckett WR (1994) Common profile of D1 receptor antagonists and atypical antipsychotic drugs revealed by analysis of dopamine turnover. Prog Neuropsychopharmacol Biol Psychiatry 18:803–821
Hirsch S, Arvanitis L, Miller B, Smith A and the Seroquel ™ Study Group (1994) A multicentre, double-blind, placebo-controlled comparison of low and high dosage regimens of Seroquel ™ in the treatment of hospitalised patients with acute exacerbation of subchronic or chronic schizophrenia. Eur Neuropsychopharmacol 4:384–385
Kane J, Honigfeld G, Singer J, Meltzer H and the Clozaril Collaborative Study Group (1988) Clozapine for the treatment-resistant schizophrenic. Arch Gen Psychiatry 45:789–796
Karlsson P, Smith L, Farde L, Harnryd C, Wiesel FA, Sedvall GC (1994) Lack of apparent antipsychotic effect of the dopamine D1-receptor antogonist SCH 39166 in schizophrenia. Neuropsychopharmacology 10 [Supplement 3, part 2]:32S
Lubin H, Gerlach J, Morkeberg F and the NNC Study Group (1994) The potential antipsychotic effects of selective D1 antagonists evaluated in monkeys and in an open clinical study. Psychopharmacology 114:B5
Mahan LC, Burch RM, Monsma FJ, Sibley DR (1990) Expression of striatal D-1 dopamine receptors coupled to inositol phosphate production and Ca2+ mobilisation in Xenopus oocytes. Proc Natl Acad Sci USA 87:2196–2200
Mailman RB, Schulz DW, Kilts CD, Lewis MH, Rollema H, Wyrick S (1986) Multiple forms of the D-1 dopamine receptor: its linkage to adenylate cyclase and psychopharmacological effects. Psychopharmacol Bull 22:593–598
Meltzer HY (1991) The mechanism of action of novel antipsychotic drugs. Schizophr Bull 17:263–287
Meltzer HY, Matsubara S, Lee JC (1989) Classification of typical and atypical antipsychotic drugs on the basis of dopamine D-1, D-2 and serotonin2 pKi values. J Pharmacol Exp Ther 251:238–246
Migler BM, Warawa EJ, Malick JB (1993) Seroquel: behavioural effects in conventional and novel tests for atypical antipsychotic drug. Psychopharmacology 112:299–307
Molloy AG, Waddington JL (1984) Dopaminergic behaviour stereospecifically promoted by the D-1 agonistR-SK&F 38393 and selectively blocked by the D-1 antagonist SCH 23390. Psychopharmacology 82:409–410
Moore NA, Tye NC, Axton MS, Risius FC (1992) The behavioural pharmacology of olanzapine, a novel “atypical” antipsychotic agent. J Pharmacol Exp Ther 262:545–551
Moore NA, Calligaro DO, Wong DT, Bymaster F, Tye NC (1993) The pharmacology of olanzapine and other new antipsychotic agents. Curr Opin Invest Drugs 2:281–293
Murray AM, Waddington JL (1989a) Further evidence for two directions of D-1:D-2 dopamine receptor interaction revealed concurrently in distinct elements of typical and atypical behaviour: studies with the new enantioselective D-2 agonist LY 163502. Psychopharmacology 98:245–250
Murray AM, Waddington JL (1989b) The induction of grooming and vacuous chewing by a series of selective D-1 dopamine receptor agonists: two directions of D-1:D-2 interaction. Eur J Pharmacol 160:377–384
Murray AM, Waddington JL (1990) The interaction of clozapine with dopamine D1 versus dopamine D2 receptor-mediated function: behavioural indices. Eur J Pharmacol 186:79–86
Rosengarten H, Schweitzer JW, Friedhoff AJ (1983) Induction of oral dyskinesias in naive rats by D-1 stimulation. Life Sci 33:2479–2482
Rosengarten H, Schweitzer JW, Friedhoff AJ (1986) Selective dopamine D-2 receptor reduction enhances a D-1 mediated oral dyskinesia in rats. Life Sci 39:29–35
Saller CF, Salama AI (1993) Seroquel: biochemical profile of a potential atypical antipsychotic. Psychopharmacology 112:285–292
Seeman P (1992) Dopamine receptor sequences: therapeutic levels of neuroleptics occupy D2 receptors, clozapine occupies D4. Neuropsychopharmacology 7:261–284
Van Tol HHM, Bunzow JR, Guan HC, Sunahare RS, Seeman P, Niznik HB (1991) Cloning of the gene for a human dopamine D4 receptor with high affinity for the antipsychotic clozapine. Nature 350:610–614
Waddington JL (1993) Pre- and postsynaptic D1 to D5 dopamine receptor mechanisms in relation to antipsychotic activity. In: Barnes TRE (ed) Antipsychotic drugs and their side effects. Academic Press, London, pp 65–85
Waddington JL (1995) The clinical psychopharmacology of antipsychotic drugs in schizophrenia. In: Hirsch SR, Weinberger DR (eds) Schizophrenia. Blackwell, Oxford, pp 341–357
Waddington JL, Daly SA (1993) Regulation of unconditioned motor behaviour by D-1:D-2 interactions. In: Waddington JL (ed) D-1:D-2 dopamine receptor interactions: neuroscience and psychopharmacology. Academic Press, London, pp 51–78
Waddington JL, Daly SA, McCauley PG, O'Boyle KM (1994) Levels of functional interaction between “D-1-like” and “D-2 like” dopamine receptor systems. In: Niznik HB (ed) Dopamine receptors and transporters. Marcel Dekker, New York, pp 511–537
Waddington JL, Daly SA, Downes RP, Deveney AM, McCauley PG, O'Boyle KM (1995) Behavioural pharmacology of “D-1-like” dopamine receptors: further subtyping, new pharmacological probes and interactions with “D-2-like” receptors. Prog Neuropsychopharmacol Biol Psychiatry (in press)
Wadenberg ML, Ahlenius S, Svensson TH (1993) Potency mismatch for behavioral and biochemical effects by dopamine receptor antagonists: implications for the mechanism of action of clozapine. Psychopharmacology 110:273–279
White FJ, Hu XT (1993) Electrophysiological correlates of D-1:D-2 interactions. In: Waddington JL (ed) D-1:D-2 dopamine receptor interactions: neuroscience and psychopharmacology. Academic Press, London, pp 79–114
Wood AJ, Beasley CM, Tollefson GD, Tran PV (1994) Efficacy of olanzapine in the positive and negative symptoms of schizophrenia. Eur Neuropsychopharmacol 4:224–225
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Deveney, A.M., Waddington, J.L. Comparison of the new atypical antipsychotics olanzapine and ICI 204,636 with clozapine on behavioural responses to the selective “D1-like” dopamine receptor agonist A 68930 and selective “D2-like” agonist RU 24213. Psychopharmacology 124, 40–49 (1996). https://doi.org/10.1007/BF02245604
Received:
Revised:
Issue Date:
DOI: https://doi.org/10.1007/BF02245604